Page last updated: 2024-08-05 13:15:08
trifluorobenzene
Any member of the class of fluorobenzenes carrying three fluorine substituents at unspecified positions.
ChEBI ID: 83576
Members (4)
Member | Definition | Role |
---|---|---|
atogepant | A secondary carboxamide resulting from the formal condensation of the carboxy group of (3'S)-2'-oxo-1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxylic acid with the amino group of (3S,5S,6R)-3-amino-6-methyl-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-2-one. It is a selective oral, small-molecule antagonist of calcitonin gene-related peptide (CGRP) receptor that has been approved for the treatment of migraine. | atogepant |
bictegravir | A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2R,5S,13aR)-8-hydroxy-7,9-dioxo-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxylic acid with the amino group of 2,4,6-trifluorobenzylamine. It is a second-generation integrase strand transfer inhibitor (INSTI) and used (as its sodium salt) for the treatment of HIV-1. | bictegravir |
fluxapyroxad | An aromatic amide obtained by formal condensation of the carboxy group of 3-(difluoromethyl)-1-methylpyrazole-4-carboxylic acid with the amino group of 3',4',5'-trifluorobiphenyl-2-amine. Used to control a number of cereal fungal pathogens including those belonging to the Ascomycetes, Basidiomycetes and Zygomycetes families. | fluxapyroxad |
sitagliptin | A triazolopyrazine that exhibits hypoglycemic activity. | sitagliptin |
Research
Studies (332)
Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 17 (5.12) | 29.6817 |
2010's | 119 (35.84) | 24.3611 |
2020's | 196 (59.04) | 2.80 |
Study Types
Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
---|---|---|
Trials | 44 (13.02%) | 5.53% |
Reviews | 42 (12.43%) | 6.00% |
Case Studies | 16 (4.73%) | 4.05% |
Observational | 8 (2.37%) | 0.25% |
Other | 228 (67.46%) | 84.16% |